New kid on the block: Roger Perl­mut­ter's biotech signs on as an­chor ten­ant to new Bay Area cam­pus

Hav­ing left be­hind a stel­lar lega­cy in Mer­ck’s head­quar­ters in Ke­nil­worth, NJ, Roger Perl­mut­ter’s next chap­ter of drug R&D will be writ­ten in the San Fran­cis­co Bay Area.

Eikon Ther­a­peu­tics, the am­bi­tious biotech start­up helmed by Perl­mut­ter, has signed a long-term lease to set up its new cor­po­rate head­quar­ters in a new life sci­ences cam­pus be­ing de­vel­oped by Alexan­dria Re­al Es­tate Eq­ui­ties in Mill­brae, CA. As the an­chor ten­ant, Eikon will com­mand about 285,000 square feet — enough to ac­com­mo­date up to 750 em­ploy­ees.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN